5-Amino-1MQ
NNMT Inhibitor — Small Molecule for Fat Oxidation
Molecular Data
- Formula
- C10H11N2
- Molecular Weight
- 159.21 g/mol
01
Overview
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme upregulated in adipose tissue that suppresses fat oxidation and energy expenditure. By blocking NNMT, 5-Amino-1MQ shifts cellular metabolism toward increased fatty acid oxidation and NAD+ production. It is studied for obesity, metabolic syndrome, and fat loss research.
02
Mechanism of Action
NNMT methylates nicotinamide to produce 1-methylnicotinamide (1-MNA), consuming SAMe and depleting cellular NAD+ pools. This shifts adipocytes toward fat storage. 5-Amino-1MQ competitively inhibits NNMT, preserving intracellular NAD+ and SAMe levels. Elevated NAD+ activates SIRT1/PGC-1α signaling, increasing mitochondrial biogenesis and fatty acid oxidation. The compound also promotes expression of uncoupling proteins in white adipose tissue, shifting it toward a brown fat-like energy-expending phenotype.
03
Research Highlights
Cellular studies demonstrate increased lipolysis and fatty acid oxidation in differentiated adipocytes
Animal models show reduced diet-induced obesity and improved insulin sensitivity with NNMT inhibition
NAD+ metabolomics studies confirm restoration of cellular NAD+ and SAMe pools following NNMT blockade
04
Dosage
Administration & Timing
Oral administration (capsule or solution) or Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue. Research protocols use once or twice daily oral administration; timing independent of food.
Dosage Guidelines
Cycle Length
4–8 weeks; research is preclinical.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 500 mg vial (for SC research)
Concentration
250 mg/mL
Storage
Store powder at room temperature; refrigerate reconstituted solution 2–8 °C.
Notes
5-Amino-1MQ is a small molecule (not a peptide) inhibiting NNMT. Oral dosing is most common in research.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
5-Amino-1MQ is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
5-Amino-1MQ Knowledge Graph
Explore how 5-Amino-1MQ connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
5-Amino-1MQ — Common Research Questions
What is 5-Amino-1MQ?
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme upregulated in adipose tissue that suppresses fat oxidation and energy exp... 5-Amino-1MQ belongs to the Weight Loss research category and is studied for its nnmt inhibitor — small molecule for fat oxidation.
How does 5-Amino-1MQ work?
NNMT methylates nicotinamide to produce 1-methylnicotinamide (1-MNA), consuming SAMe and depleting cellular NAD+ pools. This shifts adipocytes toward fat storage. 5-Amino-1MQ competitively inhibits NNMT, preserving intracellular NAD+ and SAMe levels. Elevated NAD+ activates SIRT1/PGC-1α signaling, increasing mitochondrial biogenesis and fatty acid oxidation. The compound also promotes expression of uncoupling proteins in white adipose tissue, shifting it toward a brown fat-like energy-expending phenotype.
What are the key research benefits of 5-Amino-1MQ?
NNMT enzyme inhibition restores fat oxidation capacity. Increased NAD+ levels for enhanced cellular energy metabolism. Promotes white adipose tissue browning toward energy-expending phenotype. Reduced adipocyte lipid accumulation in research models. Potential synergy with exercise and caloric restriction. Small-molecule mechanism distinct from incretin therapies.
What is the molecular structure of 5-Amino-1MQ?
5-Amino-1MQ has the molecular formula C10H11N2 and a molecular weight of 159.21 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about 5-Amino-1MQ?
Cellular studies demonstrate increased lipolysis and fatty acid oxidation in differentiated adipocytes Animal models show reduced diet-induced obesity and improved insulin sensitivity with NNMT inhibition NAD+ metabolomics studies confirm restoration of cellular NAD+ and SAMe pools following NNMT blockade These findings are based on preclinical and clinical research. 5-Amino-1MQ is a research compound and these studies do not constitute medical advice.
Is 5-Amino-1MQ FDA approved?
No. 5-Amino-1MQ is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does 5-Amino-1MQ belong to?
5-Amino-1MQ belongs to the Weight Loss category, which focuses on compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction. You can explore more compounds in this category on the Weight Loss pillar page.
Related Articles
Tesamorelin: Clinical Data for Visceral Fat Reduction
Phase III trial data showing 15-18% visceral fat reduction and the FDA approval rationale for Egrifta®.
AOD-9604: Lipolysis Without Growth Effects
How AOD-9604's C-terminus fragment of HGH stimulates lipolysis without the growth-promoting effects of full-length HGH.
CJC-1295 + Ipamorelin: Synergistic GH Secretagogue Research
Examining the complementary mechanisms of CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) in research settings.
Scientific References
Cellular studies demonstrate increased lipolysis and fatty acid oxidation in differentiated adipocytes
Animal models show reduced diet-induced obesity and improved insulin sensitivity with NNMT inhibition
NAD+ metabolomics studies confirm restoration of cellular NAD+ and SAMe pools following NNMT blockade